AU2004226517B2 - Use of ATII antagonist for the treatment or prevention of metabolic syndrome - Google Patents

Use of ATII antagonist for the treatment or prevention of metabolic syndrome Download PDF

Info

Publication number
AU2004226517B2
AU2004226517B2 AU2004226517A AU2004226517A AU2004226517B2 AU 2004226517 B2 AU2004226517 B2 AU 2004226517B2 AU 2004226517 A AU2004226517 A AU 2004226517A AU 2004226517 A AU2004226517 A AU 2004226517A AU 2004226517 B2 AU2004226517 B2 AU 2004226517B2
Authority
AU
Australia
Prior art keywords
angiotensin
receptor antagonist
type
use according
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004226517A
Other languages
English (en)
Other versions
AU2004226517A1 (en
Inventor
Anders Ljunggren
Anders Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2004226517A1 publication Critical patent/AU2004226517A1/en
Application granted granted Critical
Publication of AU2004226517B2 publication Critical patent/AU2004226517B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004226517A 2003-04-03 2004-03-31 Use of ATII antagonist for the treatment or prevention of metabolic syndrome Ceased AU2004226517B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300988-3 2003-04-03
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome

Publications (2)

Publication Number Publication Date
AU2004226517A1 AU2004226517A1 (en) 2004-10-14
AU2004226517B2 true AU2004226517B2 (en) 2008-01-24

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004226517A Ceased AU2004226517B2 (en) 2003-04-03 2004-03-31 Use of ATII antagonist for the treatment or prevention of metabolic syndrome

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067378A2 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20060194856A1 (en) 2006-08-31
MXPA05010660A (es) 2005-12-12
IL170706A0 (en) 2009-02-11
NZ542640A (en) 2008-06-30
AU2004226517A1 (en) 2004-10-14
NO20054370D0 (no) 2005-09-21
ZA200507945B (en) 2007-04-25
WO2004087136A1 (en) 2004-10-14
CN1771033A (zh) 2006-05-10
KR20050114671A (ko) 2005-12-06
BRPI0408979A (pt) 2006-04-04
CA2520960A1 (en) 2004-10-14
JP2006522115A (ja) 2006-09-28
EP1613309A1 (en) 2006-01-11
NO20054370L (no) 2005-10-31
SE0300988D0 (sv) 2003-04-03

Similar Documents

Publication Publication Date Title
CA2904447C (en) Therapy for complications of diabetes
EP1572196B1 (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
JP5425631B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
Stein et al. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia
PT1467728E (pt) Composições farmacêuticas compreendendo valsartan e inibidores da nep
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
AU2004226517B2 (en) Use of ATII antagonist for the treatment or prevention of metabolic syndrome
US20100105746A1 (en) Method for treating metabolic diseases
JP2018521077A (ja) 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
AU2012346754B2 (en) Pharmaceutical composition for preventing or treating hyperlipidemia
WITTENBERG¹ et al. Long-Term (12-Month) Antihypertensive, Metabolic, and Renal Hemodynamic Effects of
NZ625006B2 (en) Pharmaceutical composition for preventing or treating hyperlipidemia
JP2009256209A (ja) 降圧療法
HK1085377B (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
HK1107677A (en) Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired